Viewing
|Videos|October 2, 2020

Bayer discusses relevant clinical study results

Patrick Bussfeld, MD, VP, head medical affairs ophthalmology at Bayer Consumer Care AG, discusses the results from several treat-and-extend studies on aflibercept, and how Bayer is participating in the 2020 EURETINA virtual meeting.


Patrick Bussfeld, MD, VP, head medical affairs ophthalmology at Bayer Consumer Care AG, discusses the results from several treat-and-extend studies on aflibercept, and how Bayer is participating in the 2020 EURETINA virtual meeting.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe

Latest CME